Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Novo-Nordisk A/S (NYSE:NVO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs
Recent Events
Aug  7Earnings Announcement
Aug  6Price hit new 52-week high ($46.30)
Location
Novo Alle, DK-2880 Bagsvaerd
Denmark, Denmark
Phone: (212) 867-0123
Fax: (212) 867-0298
Employees (last reported count): 13,752
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Divisions
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 29%
·Institutional: 2% (3% of float)
(82 institutions)
·Net Inst. Selling: 9.00M shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Novo-Nordisk A/S is a focused healthcare company. The Company has a broad diabetes product portfolio that includes advanced products within the area of insulin delivery systems. In addition, Novo Nordisk is engaged in areas such as coagulation disorders, human growth hormone and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that are designed to make a significant difference to patients, the medical profession and society. In early 1999, it was decided that Novo Nordisk would de-merge into two main businesses, Healthcare and Enzymes. The de-merger enables the two businesses to increase their operational freedom and focus on what they do best. On November 14, 2000 Novo Nordisk and Novozymes began operating as two separate listed companies.
More from Market Guide: Expanded Business Description

Financial Summary
NVO is a healthcare company that specializes in products for the treatment of diabetes, as well as products in the areas of coagulation disorders, human growth hormone and hormone replacement. For the fiscal year ended 12/00, revenues rose 27% to DKK20.81 billion. Net income according to U.S. GAAP rose 45% to DKK3.56 billion. Revenues reflect increased sale of Diabetes care and Coagulation Disorder products. Earnings also reflect a decrease in production costs.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 6,001,000; after tax earnings were 887,000. (Preliminary; reported in thousands of Danish Krone.)

More from Market Guide: Significant Developments

Officers

Position
Mads ØvlisenChairman
Lars Rebien SorensenPres, CEO
Jesper BrandgaardCFO
Lars Almblom JorgensenCOO
Mads Krogsgaard ThomsenCSO
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NYSE:NVOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Nov-2000
$32.70 
Recent Price$41.60 
52-Week High
on 6-Aug-2001
$46.30 
Beta0.14 
Daily Volume (3-month avg)18.1K
Daily Volume (10-day avg)11.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+1.1%
52-Week Change
relative to S&P500
+35.6%
Share-Related Items
Market Capitalization$12.7B
Shares Outstanding306.2M
Float218.5M
Dividends & Splits
Annual Dividendnone 
Last Split: 5 for 2 on 11-Apr-2001
Per-Share Data
Book ValueN/A 
Earnings (ttm)$1.35 
Earnings (mrq)$0.31 
SalesN/A 
CashN/A 
Valuation Ratios
Price/BookN/A 
Price/Earnings (ttm)30.86 
Price/SalesN/A 
Income Statements
SalesN/A 
EBITDAN/A 
IncomeN/A 
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on AssetsN/A 
Return on EquityN/A 
Financial Strength
Current RatioN/A 
Debt/EquityN/A 
Total Cash (mrq)$0 
Short Interest
As of 8-Aug-2001
Shares Short45.0K
Percent of Float0.0%
Shares Short
(Prior Month)
62.0K
Short Ratio2.50 
Daily Volume18.0K
ADR Information
Shares/ADR1
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001);   dollar amounts based on an exchange rate of 8.18 Danish Krone/Dollar

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.